Breaking News Instant updates and real-time market news.

SGMO

Sangamo

$11.65

0.05 (0.43%)

, PFE

Pfizer

$38.29

0.26 (0.68%)

09:14
12/07/19
12/07
09:14
12/07/19
09:14

Sangamo, Pfizer announce follow-up results from Phase 1/2 hemophilia A.study

Sangamo Therapeutics (SGMO) and Pfizer (PFE) announced updated follow-up results from the Phase 1/2 Alta study evaluating investigational SB-525 gene therapy in patients with severe hemophilia A. The data showed that SB-525 was generally well tolerated and demonstrated sustained increased Factor VIII levels following treatment with SB-525 through to 44 weeks, the extent of follow-up for the longest treated patient in the 3e13 vg/kg dose cohort, the companies said.. Data from 11 patients treated with SB-525 will be featured in a poster presentation today at the Annual Meeting of the American Society of Hematology. In the 3e13 vg/kg dose cohort, patients achieved normal range FVIII activity within 5-7 weeks of treatment with SB-525, the companies added. "We are pleased with the progress that we have made in progressing SB-525 gene therapy toward a Phase 3 registrational study, including enrolling the first patient in the 6-month lead-in study. We expect to dose the first patient in the Phase 3 registrational study in 2020," said Seng Cheng, Senior Vice President and Chief Scientific Officer of Pfizer's Rare Diseases Research Unit. "We continue to believe that if the observed safety and efficacy results are sustained, this gene therapy has the potential to transform the treatment paradigm of severe hemophilia A."

SGMO

Sangamo

$11.65

0.05 (0.43%)

PFE

Pfizer

$38.29

0.26 (0.68%)

  • 07

    Dec

  • 09

    Dec

  • 11

    Dec

SGMO Sangamo
$11.65

0.05 (0.43%)

07/12/19
JEFF
07/12/19
NO CHANGE
Target $19
JEFF
Buy
Sangamo should be bought at current share levels, says Jefferies
Jefferies analyst Maury Raycroft attributes the recent weakness in shares of Sangamo Therapeutics (SGMO) to negative sentiment related to BioMarin's (BMRN) valrox's durability. The market may be assuming all hemophilia A gene therapies are the same, Raycroft tells investors in a research note. However, he believes Sangamo's SB-525 could be "best-in-class" and keeps a Buy rating on the shares with a $19 price target. The analyst recommends buying the stock at current levels for the company's hemophilia A opportunity and "robust" pipeline.
07/26/19
ADAM
07/26/19
NO CHANGE
Target $37
ADAM
Buy
Homology Medicines selloff yesterday a buying opportunity, says Canaccord
Canaccord Genuity analyst Michelle Gilson attributes the selloff yesterday in shares of Homology Medicines (FIXX) to a pre-printed, and not peer-reviewed, paper that did not support the company's in vitro data around HR-mediated gene editing. The paper's author, who has previously worked with Sangamo Therapeutics (SGMO) on ZFN-mediated editing, was unable to induce homologous recombination without a nuclease, Gilson tells investors in a research note. "It is tough to understand why an author would choose this route of publication for a study of this nature," says the analyst. She sees "several key differences" between the author's and Homology's in vitro experiments. Further, Homology's technology has been externally validated, allowing Novartis (NVS) and other labs to perform their own in-house experiments using Homology plasmids, Gilson contends. She adds that following this validation, Novartis entered into a collaboration specifically revolving around Homology's gene editing technology for ophthalmic targets. The analyst keeps a Buy rating on Homology Medicines with a $37 price target. Gilson views the selloff in the shares as a buying opportunity into the Phase 1/2 pheNIX data by the end of 2019 for HMI-102 gene therapy in phenylketonuria.
08/26/19
HCWC
08/26/19
INITIATION
Target $16
HCWC
Buy
Sangamo initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay started Sangamo Therapeutics with a Buy rating and $16 price target. The shares have further upside "as the Street recalibrates its view with an eye towards an expansive pipeline that leverages the company's core competence in ZFN-based genome editing, but in an ex vivo environment with potentially more predictable and controllable deliverables," Chattopadhyay tells investors in a research note.
08/26/19
08/26/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Sangamo (SGMO) initiated with a Buy at H.C. Wainwright. 2. iHeartMedia (IHRT) initiated with an Equal Weight at Morgan Stanley. 3. Kura Sushi (KRUS) initiated with an Overweight at Stephens, an Outperform at BMO Capital, and a Buy at BTIG. 4. Sundial Growers (SNDL) initiated with a Neutral at CIBC and an Outperform at Cowen. 5. New Relic (NEWR) initiated with an Equal Weight at Barclays. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
PFE Pfizer
$38.29

0.26 (0.68%)

11/01/19
RAJA
11/01/19
UPGRADE
Target $24
RAJA
Outperform
Intellia Therapeutics upgraded to Outperform at Raymond James
Raymond James analyst Steven Seedhouse upgraded Intellia Therapeutics to Outperform from Market Perform with a $24 price target. In a research note to investors, Seedhouse says Intellia's NTLA-2001 is poised to benefit from the "heavy lifting" Pfizer (PFE) is doing commercially with Vyndaqel in ATTR-cardiomyopathy, adding that Intellia is also advancing manufacturing related activities in support of a Phase 1 trial for engineered cell program WT1-TCR in AML. The analyst also says Intellia's lead gene editing program, NTLA-2001 has "really good" primate data showing TTR knockdown potentially better than Alnylam's (ALNY) patisiran. He expects the market will already start to impute downstream clinical benefit for NTLA-2001 after only a few patients with initial TTR knockdown data, because of the collective data for Ionis Pharmaceuticals' (IONS) inotersen and Alnylam's patisiran showing knockdown is relevant.
11/06/19
PIPR
11/06/19
NO CHANGE
Target $70
PIPR
Neutral
Ionis Pharmaceuticals price target lowered to $70 from $75 at Piper Jaffray
Piper Jaffray analyst Tyler Van Buren lowered his price target on Ionis Pharmaceuticals (IONS) to $70 and kept his Neutral rating after its Q3 results, saying that while the quarter was "strong" thanks to the recent $250M upfront payment from Pfizer (PFE), results for its Tegsedi were "uninspiring". The analyst states that an acceleration in Tegsedi is needed soon for him to become more positive on the name ahead of the "potential Phase I/II OLE +natural history Huntington's study readouts next year."
11/12/19
PIPR
11/12/19
NO CHANGE
Target $185
PIPR
Overweight
Time to dismiss Solid Biosciences as Sarepta competitor, says Piper Jaffray
Piper Jaffray analyst Danielle Brill says that while she had dismissed Solid Biosciences' (SLDB) microdystophin gene therapy program as a competitive threat to Sarepta Therapeutics (SRPT), some investors worried that Solid could provide compelling data after adjusting protocol and moving up the dose. However, today's report of another clinical hold confirms that Solid's construct is toxic, indicating that Pfizer's (PFE) may to too, Brill tells investors in a research note. The analyst points out that both Solid and Pfizer use AAV9 and have had complement mediated serious adverse events after dosing just a few patients. Solid's program reaffirms her view that Sarepta's safety profile is differentiated. It is unlikely that the competition "is viable, let alone will ever catch up," says Brill. She keeps an Overweight rating on Sarepta Therapeutics with a $185 price target. The stock in midday trading is up 4% to $99.02 while Solid Biosciences is down 71% to $3.22.
11/25/19
PIPR
11/25/19
INITIATION
Target $2.5
PIPR
Overweight
Opko Health initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff initiated coverage of Opko Health (OPK) with an Overweight rating and $2.50 price target. The company's partner Pfizer (PFE) recently reported positive Phase III data on once-weekly somatrogo in pediatric growth hormone deficiency, Tenthoff tells investors in a research note. The analyst is confident in the drug and notes that Opko is eligible for up to $275M in milestones plus gross profit share on Genotropin and somatrogon revenue.

TODAY'S FREE FLY STORIES

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
01/17/20
01/17
11:17
01/17/20
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
01/17/20
01/17
11:16
01/17/20
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNIT

Uniti Group

$7.45

-0.49 (-6.17%)

11:15
01/17/20
01/17
11:15
01/17/20
11:15
Options
Uniti Group put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:10
01/17/20
01/17
11:10
01/17/20
11:10
General news
Today's U.S. reports »

Today's U.S. reports…

STT

State Street

$84.45

3.445 (4.25%)

11:08
01/17/20
01/17
11:08
01/17/20
11:08
Periodicals
State Street held talks to find buyer for Currenex, FT reports »

State Street has held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 31

    Jan

  • 26

    Feb

10:55
01/17/20
01/17
10:55
01/17/20
10:55
General news
U.S. equities are modestly firmer at fresh record highs »

U.S. equities are…

ERIC

Ericsson

$9.01

-0.075 (-0.83%)

10:55
01/17/20
01/17
10:55
01/17/20
10:55
Options
Ericsson put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

10:55
01/17/20
01/17
10:55
01/17/20
10:55
General news
FX Action: USD-JPY »

FX Action: USD-JPY…

JBLU

JetBlue

$19.30

0.28 (1.47%)

10:45
01/17/20
01/17
10:45
01/17/20
10:45
Options
JetBlue call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

10:40
01/17/20
01/17
10:40
01/17/20
10:40
General news
FX Action: USD-CAD »

FX Action: USD-CAD has…

ES

Eversource

$87.74

0.01 (0.01%)

, CMS

CMS Energy

$65.28

-0.1 (-0.15%)

10:32
01/17/20
01/17
10:32
01/17/20
10:32
Downgrade
Eversource, CMS Energy, NextEra Energy rating change  »

NextEra, CMS Energy,…

ES

Eversource

$87.74

0.01 (0.01%)

CMS

CMS Energy

$65.28

-0.1 (-0.15%)

NEE

NextEra Energy

$251.86

-0.41 (-0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 24

    Jan

  • 30

    Jan

  • 12

    Mar

  • 13

    Mar

TWTR

Twitter

$34.14

-0.05 (-0.15%)

, SNAP

Snap

$19.15

0.9 (4.93%)

10:31
01/17/20
01/17
10:31
01/17/20
10:31
On The Fly
Analysts bullish on Pinterest, Snap as Twitter gets downgraded to Neutral »

Shares of social media…

TWTR

Twitter

$34.14

-0.05 (-0.15%)

SNAP

Snap

$19.15

0.9 (4.93%)

PINS

Pinterest

$23.30

0.34 (1.48%)

FB

Facebook

$221.31

-0.47 (-0.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 29

    Jan

  • 04

    Feb

  • 06

    Feb

  • 06

    Feb

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

10:30
01/17/20
01/17
10:30
01/17/20
10:30
Options
Busy week for 50 Cent as another massive block of calls is bought »

Busy week for 50 Cent as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLAY

Dave & Buster's

$47.28

5.23 (12.44%)

, KKR

KKR

$31.17

0.67 (2.20%)

10:30
01/17/20
01/17
10:30
01/17/20
10:30
Periodicals
KKR not discussing going hostile on Dave & Buster's, Axios reports »

KKR (KKR) has a…

PLAY

Dave & Buster's

$47.28

5.23 (12.44%)

KKR

KKR

$31.17

0.67 (2.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jan

  • 31

    Jan

  • 26

    Feb

VWAGY

Volkswagen

$0.00

(0.00%)

10:28
01/17/20
01/17
10:28
01/17/20
10:28
Periodicals
VW set to acquire 20% stake in Chinese battery maker Guoxuan, Reuters reports »

Volkswagen is poised to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LIZI

Lizhi

$0.00

(0.00%)

10:26
01/17/20
01/17
10:26
01/17/20
10:26
Syndicate
Lizhi opens at $11.03, IPO priced at $11.00 per share »

Lizhi (LIZI) priced 4.1M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

10:25
01/17/20
01/17
10:25
01/17/20
10:25
Conference/Events
Wolfe Research tech strategist to hold an analyst/industry webcast »

Tech Strategist…

10:25
01/17/20
01/17
10:25
01/17/20
10:25
Conference/Events
UBS services analysts to hold an analyst/industry conference call »

Services Analyst Lasser,…

10:25
01/17/20
01/17
10:25
01/17/20
10:25
Conference/Events
Wolfe Research industrials analysts to hold an analyst/industry webcast »

Multi-Idndustry Analyst…

10:25
01/17/20
01/17
10:25
01/17/20
10:25
Conference/Events
JPMorgan U.S. telecom & semis analysts hold an analyst/industry conference call »

U.S. Telecom &…

10:25
01/17/20
01/17
10:25
01/17/20
10:25
Conference/Events
Cowen Washington policy strategist to hold an analyst/industry conference call »

Washington Policy…

MIDD

Middleby

$111.11

1.51 (1.38%)

, MCD

McDonald's

$212.00

1.14 (0.54%)

10:24
01/17/20
01/17
10:24
01/17/20
10:24
Recommendations
Middleby, McDonald's, Welbilt analyst commentary  »

Middleby equimpment may…

MIDD

Middleby

$111.11

1.51 (1.38%)

MCD

McDonald's

$212.00

1.14 (0.54%)

WBT

Welbilt

$15.39

-0.06 (-0.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

CMS

CMS Energy

$65.31

-0.07 (-0.11%)

10:24
01/17/20
01/17
10:24
01/17/20
10:24
Downgrade
CMS Energy rating change  »

CMS Energy downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

  • 12

    Mar

  • 13

    Mar

ES

Eversource

$87.64

-0.09 (-0.10%)

10:24
01/17/20
01/17
10:24
01/17/20
10:24
Downgrade
Eversource rating change  »

Eversource downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

NEE

NextEra Energy

$252.14

-0.13 (-0.05%)

10:23
01/17/20
01/17
10:23
01/17/20
10:23
Downgrade
NextEra Energy rating change  »

NextEra Energy downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.